<DOC>
	<DOCNO>NCT02013804</DOCNO>
	<brief_summary>This multicenter , open label , first-in-human dose-escalation study MEDI0680 ( AMP-514 ) evaluate safety , tolerability , PK , immunogenicity ( IM ) , antitumor activity adult subject solid tumor .</brief_summary>
	<brief_title>A Phase 1 Multicenter Open-label Study Evaluate Safety Tolerability PK MEDI0680 ( AMP-514 ) Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . At least 18 year age time study entry 2 . Written inform consent locally require authorization ( eg , Health Insurance Portability Accountability Act [ HIPAA ] USA ) obtain subject/legal representative prior performing protocolrelated procedure , include screen evaluation 3 . Histologically cytologicallyconfirmed melanoma clearcell RCC refractory standard therapy standard therapy exist 1 . Subjects must fail , intolerant , ineligible potentially curative approve treatment , irrespective line therapy 2 . No 3 prior line therapy 4 . At least 1 measurable lesion per RECIST v1.1 ; subject whose measurable lesion lymph node exclude 5 . Eastern Cooperative Oncology Group performance score 0 1 6 . For tumor type , adequate organ marrow function , define : 1 . Hemoglobin ³ 9.0 g/dL within first 2 week prior first dose MEDI0680 ( AMP514 ) 2 . Absolute neutrophil count ( ANC ) ³ 1.5 × 109/L ( 1,500/mm3 ) 3 . Platelet count ³ 100 × 109/L ( 100,000/mm3 ) 4 . Total bilirubin ≤ 1.5 × ULN except subject document Gilbert 's syndrome ( &gt; 3 × ULN ) liver metastasis , must baseline total bilirubin ≤ 3.0 mg/ 5 . Alanine aminotransferase AST ≤ 2.5 × ULN ; subject hepatic metastasis , ALT AST ≤ 5 × ULN 6 . Serum creatinine ≤ 1.5 × ULN OR calculate creatinine clearance ( CrCl ) 24hour urine CrCl ≥ 50 mL/minute ▪ CockcroftGault formula use calculate CrCl ; 24hour urine CrCl derive use measure creatinine clearance formula 7 . Prior treatment toxicity must ≤ Grade 1 1 . Concurrent enrollment another clinical study , unless observational ( noninterventional ) clinical study followup period interventional study 2 . Receipt BRAF inhibitor ( metastatic melanoma ) , investigational anticancer therapy within 4 week prior first dose MEDI0680 ( AMP514 ) 3 . Prior exposure immunotherapy , , limit , antiCTLA4 , antiPD1 , antiPDL1 antibody , exclude therapeutic cancer vaccine 4 . Major surgery ( define investigator ) within 4 week prior first dose MEDI0680 ( AMP514 ) still recover prior surgery 5 . Other invasive malignancy within 2 year except noninvasive malignancy cervical carcinoma situ , nonmelanomatous carcinoma skin ductal carcinoma situ breast has/have surgically cure 6 . Prior allogeneic autologous bone marrow organ transplantation require use immunosuppressive 7 . Unresolved toxicity prior anticancer therapy , define resolve NCI CTCAE v4.03 Grade 0 1 , level dictate inclusion/exclusion criterion exception alopecia . Subjects irreversible toxicity reasonably expect exacerbated MEDI0680 ( AMP514 ) may include ( eg , hearing loss ) consultation MedImmune medical monitor 8 . Active prior document autoimmune disease within past 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>